Financial Results for the quarter ended June 30, 2026
RESULTS
◆ Monitor Closely
LOW RISK
📅 Filed on BSE: 31 Jul 2026, 07:20 PM IST · BSE ID: a83126c3-51b2-443b-9b18-a85681a7fa63
View Original BSE Filing (PDF)
💡
In Simple Terms
Aarti Drugs announced its financial results, showing a consolidated profit of Rs. 5,013 lakhs for the recent quarter.
🤖 AI Summary
- Aarti Drugs Ltd reported a consolidated profit of Rs. 5,013 lakhs for the quarter ended June 30, 2026.
- Standalone profit for the quarter ended June 30, 2026, was Rs. 5,085 lakhs.
- The Board of Directors approved the audited standalone and consolidated financial results on July 31, 2026.
- Consolidated Revenue from Operations for Q1 FY27 stood at Rs. 70,278 lakhs.
- Exceptional item of Rs. 209 lakhs recorded as a write-off of Capital Work-in-Progress.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from operations (Q1 FY27)
Rs. 70,278 lakhs
18.99%
Consolidated Profit / (Loss) for the Year (Q1 FY27)
Rs. 5,013 lakhs
-7.01%
Standalone Revenue from operations (Q1 FY27)
Rs. 62,745 lakhs
20.44%
Standalone Profit / (Loss) for the Year (Q1 FY27)
Rs. 5,085 lakhs
4.54%
Exceptional Item
Rs. 209 lakhs
🏢 How This Affects the Company
The company reported a consolidated profit of Rs. 5,013 lakhs and standalone profit of Rs. 5,085 lakhs for the quarter. Consolidated total income was Rs. 70,309 lakhs.
An exceptional item of Rs. 209 lakhs was a write-off of Capital Work-in-Progress (CWIP) for an administrative building, indicating an adjustment in asset valuation.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as these results reflect the company's financial health and operational performance for the quarter ended June 30, 2026.
🔍
Management Signal
Management is providing statutory disclosure of quarterly financial performance as per regulatory requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check revenue and profit trends.
Update on Capital Work-in-Progress write-off impact.
Any future announcements regarding routine expansion plans.
LOW RISK
This is a routine financial results disclosure with no immediate new risks identified.
💡 Investor Takeaway
Aarti Drugs Ltd reported a consolidated profit of Rs. 5,013 lakhs for Q1 FY27, with consolidated revenue from operations at Rs. 70,278 lakhs. Standalone profit was Rs. 5,085 lakhs. The results were approved on July 31, 2026.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated total income reached Rs. 70,309 lakhs for the quarter ended June 30, 2026, compared to Rs. 59,082 lakhs in the prior year comparable quarter.
- Standalone total income increased to Rs. 62,875 lakhs in Q1 FY27 from Rs. 52,127 lakhs in the same quarter last year.
⚠️ Concerns
- Consolidated Profit / (Loss) for the Year decreased to Rs. 5,013 lakhs in Q1 FY27 from Rs. 5,391 lakhs in Q1 FY26.
- Standalone Profit / (Loss) for the Year decreased to Rs. 5,085 lakhs in Q1 FY27 from Rs. 4,864 lakhs in Q1 FY26, after an exceptional item.
📅 Company Track Record
Aarti Drugs reported FY26 Consolidated Profit of Rs. 19,494 lakhs in May 2026, showing a 16.09% YoY increase. The current Q1 FY27 results follow board approval for the financial period ending June 30, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Aarti Drugs Ltd's consolidated net profit for Q1 FY27?
Aarti Drugs Ltd reported a consolidated Profit / (Loss) for the Year of Rs. 5,013 lakhs for the quarter ended June 30, 2026.
What was Aarti Drugs Ltd's standalone net profit for Q1 FY27?
Aarti Drugs Ltd's standalone Profit / (Loss) for the Year was Rs. 5,085 lakhs for the quarter ended June 30, 2026.
What was Aarti Drugs Ltd's consolidated revenue from operations in Q1 FY27?
Consolidated Revenue from operations for Aarti Drugs Ltd was Rs. 70,278 lakhs for the quarter ended June 30, 2026.
What was the exceptional item reported by Aarti Drugs Ltd in Q1 FY27?
An exceptional item of Rs. 209 lakhs was reported, representing a write-off of Capital Work-in-Progress (CWIP) pertaining to an administrative building.
When were the Q1 FY27 financial results for Aarti Drugs Ltd approved?
The Board of Directors of Aarti Drugs Ltd approved the audited standalone and consolidated financial results for the quarter ended June 30, 2026, on July 31, 2026.
Questions based on this BSE filing only. For information purposes.